Culley Deirdre May, Taylor Jirka, Rubin Jennifer, Hoorens Stijn, Disley Emma, Rabinovich Lila
Rand Health Q. 2012 Jun 1;2(2):15. eCollection 2012 Summer.
Illicit drug use continues to be an important public health and safety concern in Europe. Production, trafficking and dealing in illicit drugs constitute important criminal justice challenges in themselves, and are associated with other criminal activities. The 2005-2012 EU Drugs Strategy (as with previous strategies) was developed to complement and add value to national strategies and approaches while respecting the principles of subsidiarity and proportionality set out in the EU Treaties. The main rationale for its development was that while drugs problems vary across Member States, and are experienced at the local and national level, they are "a global issue that needs to be addressed in a transnational context." RAND Europe undertook an independent evaluation of the current Strategy and its Action Plans, addressing four research objectives: (1) to assess barriers and facilitators to the implementation of objectives and priorities at EU and Member State level, (2) to assess the relevance and influence of the Strategy with respect to national drugs policy and legislation, (3) to assess possible impact on the drugs situation in the EU, and (4) to identify key aspects and recommendations for future EU Drugs Strategies.
在欧洲,非法药物的使用仍然是一个重要的公共卫生与安全问题。非法药物的生产、贩运和交易本身就构成了重大的刑事司法挑战,并且与其他犯罪活动相关联。2005 - 2012年欧盟毒品战略(与之前的战略一样)旨在补充并提升国家战略和方法的价值,同时尊重欧盟条约中规定的辅助性原则和相称性原则。制定该战略的主要理由是,虽然毒品问题在各成员国之间存在差异,且在地方和国家层面有所体现,但它们“是一个全球性问题,需要在跨国背景下加以解决”。欧洲兰德公司对当前战略及其行动计划进行了独立评估,涉及四个研究目标:(1)评估欧盟和成员国层面实施目标及优先事项的障碍与促进因素;(2)评估该战略对国家毒品政策和立法的相关性及影响;(3)评估对欧盟毒品形势可能产生的影响;(4)确定未来欧盟毒品战略的关键方面及建议。